{"schema_version":"1.0","canonical_url":"https://patentable.app/patents/US-9803245","patent":{"patent_number":"US-9803245","title":"Signature for predicting clinical outcome in human HER2+ breast cancer","assignee":null,"inventors":[],"filing_date":"2013-03-14T00:00:00.000Z","publication_date":"2017-10-31T00:00:00.000Z","cpc_codes":["C12Q","G01N","G01N","C12Q","C12Q"],"num_claims":9,"abstract":"A method of predicting outcome in a subject with for example Her2+ (ERα−) breast cancer comprising: (a) determining a HTICs expression signature comprising determining an expression level of 2 or more HTICS biomarkers selected from Aurkb, Ccna2, Scrn1, Npy, Atp7b, Chaf1b, Ccnb1, Cldn8, Nrp1, Ccr2, C1qb, Cd74, Vcam1, Cd180, Itgb2, Cd72, St8sia4, Kif11, Plk1, Chek1, Mphosph6, Cora1a, Ccl5, Cd3e, Hcls1, Vav1, Plek, Arhgdib, Il2rg, Sash3, Lck, Il2rb, Cybb, Cd79b, Sell, Ccnd2, Tnfrsf1b, Rftn1, Rac2 and Ly86; and (b) calculating a signature score, the signature score comprising a sum of HTICs biomarker expression parameters; wherein a signature score greater than a selected cut-off or control signature score is indicative of a poor outcome (HTICS+) and a signature score less than a selected cut-off is indicative of a good outcome (HTICS−). The methods can be used to prognose outcome and/or select suitable treatment. Arrays and kits for use with the methods are also provided."},"analysis":{"summary":null,"layman_explanation":null,"technical_analysis":null,"business_analysis":null,"faqs":null,"topics":[],"tech_cluster":null},"seo":{"title":"Signature for predicting clinical outcome in human HER2+ breast cancer","description":"A method of predicting outcome in a subject with for example Her2+ (ERα−) breast cancer comprising: (a) determining a HTICs expression signature comprising determining an expression level of 2 or more","keywords":[]},"attribution":{"source":"Patentable","source_url":"https://patentable.app","canonical_url":"https://patentable.app/patents/US-9803245","license":"CC-BY-4.0-like","license_terms":"AI-generated analysis on this page (summary, layman_explanation, technical_analysis, business_analysis, faqs) may be reused with attribution and a visible link back to the canonical URL above. Patent abstracts, claims, and bibliographic data are USPTO public domain.","required_link":"https://patentable.app/patents/US-9803245","citation_suggestion":"Patentable. \"Signature for predicting clinical outcome in human HER2+ breast cancer\" (US-9803245). https://patentable.app/patents/US-9803245","copyright_holder":"Nomic Interactive Technology LLC"},"links":{"html":"https://patentable.app/patents/US-9803245","json":"https://patentable.app/api/llm-context/US-9803245","site":"https://patentable.app","llms_txt":"https://patentable.app/llms.txt"},"generated_at":"2026-06-06T10:18:46.632Z"}